Bacterial Vaginosis Market to Register Incremental Growth During the Study Period (2020–2034) | DelveInsight

New York, USA, July 15, 2024 (GLOBE NEWSWIRE) -- Bacterial Vaginosis Market to Register Incremental Growth During the Study Period (2020–2034) | DelveInsight The current therapeutic landscape of bacterial vaginosis is driven by approved therapies such as XACIATO, SOLOSEC, and VivaGel. The launch of novel developmental candidates currently in the emerging portfolio is expected to create a positive impact on the overall therapeutic landscape catering treatment options during the forecast period (2024–2034).DelveInsight's Bacterial Vaginosis Market Insights report includes a comprehensive understanding of current treatment practices, bacterial vaginosis emerging drugs, market share of individual therapies, and current and forecasted bacterial vaginosis market size from 2020 to 2034, segmented into 7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan].Key Takeaways from the Bacterial Vaginosis Market ReportAccording to DelveInsight's analysis, the market size of bacterial vaginosis in the 7MM is expected to grow at a significant CAGR by 2034.Bacterial vaginosis is the most common vaginal infection found in women of reproductive age and is estimated to occur in anywhere from 5–70% of women. In the United States, about 30% of women ages between 14–49 are affected, however, rates are variable between different ethnic groups and are most common in non-white women.Prominent companies working in the domain of bacterial vaginosis, including Osel, Siolta Therapeutics, Gedea Biotech, and others, are actively working on innovative drugs for bacterial vaginosis. These novel bacterial vaginosis therapies are anticipated to enter the bacterial vaginosis market in the forecast period and are expected to change the market.Some of the key therapies for bacterial vaginosis treatment include LACTIN-V, STMC-105, pHyph, and others. Discover which therapies are expected to grab the bacterial vaginosis market share @ Bacterial Vaginosis Market ReportBacterial Vaginosis OverviewBacterial vaginosis, also known as nonspecific vaginitis, is a vaginal condition characterized by an overgrowth of certain bacteria, leading to vaginal discharge. It is the most common form of infectious vaginitis. The risk factors for bacterial vaginosis mirror those for sexually transmitted infections. Notable risk factors include antibiotic use, intrauterine devices for birth control, and cigarette smoking, all of which increase the likelihood of developing bacterial vaginosis.Bacterial vaginosis can elevate the risk of several complications, such as pelvic inflammatory disease, endometritis post-abortion, postpartum, and posthysterectomy vaginal cuff infection. During pregnancy, it is linked to a higher risk of chorioamnionitis, premature rupture of membranes, preterm labor, and preterm birth.Many women with bacterial vaginosis exhibit no symptoms. However, when symptoms are present, they typically include an abnormal amount of vaginal discharge, thin and grayish-white discharge, and a vaginal odor. These symptoms can occur at any point in the menstrual cycle, including before, during, or after menstruation.Bacterial Vaginosis Epidemiology SegmentationThe bacterial vaginosis epidemiology section provides insights into the historical and current bacterial vaginosis patient pool and forecasted trends for the 7MM. It helps recognize the causes of current and forecasted patient trends by exploring numerous studies and views of key opinion leaders.The bacterial vaginosis market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:Prevalent Cases of Bacterial VaginosisDiagnosed Prevalent Cases of Bacterial VaginosisAge-Specific Diagnosed Prevalent Cases of Bacterial VaginosisTreatable Cases of Bacterial VaginosisDownload the report to understand which factors are driving bacterial vaginosis epidemiology trends @ Bacterial Vaginosis Epidemiological InsightsBacterial Vaginosis Treatment Market The primary treatment options for bacterial vaginosis currently include metronidazole, clindamycin in either oral or vaginal suppository form, and metronidazole vaginal gel. Although up to 30% of BV cases may resolve on their own without treatment, the condition can be effectively treated with either clindamycin or metronidazole, both of which can be administered orally or vaginally. Additionally, these medications are safe for use during pregnancy. Secnidazole, which has been around since the late 1960s, is not widely known among US healthcare providers. The most recent addition to the US market is Solosec (secnidazole), which was approved in 2017 specifically for bacterial vaginosis. Solosec was the first therapy in the US to receive FDA approval for bacterial vaginosis and was designated as a Qualified Infectious Disease Product (QIDP) with Fast Track status.In December 2021, Daré announced that the FDA approved XACIATO (clindamycin phosphate) vaginal gel, 2% (previously known as DARE-BV1) for treating bacterial vaginosis in females aged 12 and older. In June 2022, Organon, a global women's healthcare company, and Daré Bioscience announced the completion of an agreement in which Organon acquired the global licensing rights to XACIATO (clindamycin phosphate) vaginal gel 2%.Another authorized treatment is VivaGel BV, a mucoadhesive gel approved in Europe in 2019. It is the first non-antibiotic treatment for preventing recurrent BV. Consequently, it holds QIDP and Fast Track status for these indications in various markets.Learn more about the FDA-approved drugs for bacterial vaginosis @ Drugs for Bacterial Vaginosis Treatment Bacterial Vaginosis Emerging Drugs and CompaniesThe dynamics of the bacterial vaginosis treatment market are anticipated to change during the forecast period as companies across the 7MM are diligently working towards the development of novel treatment options to combat the existing treatment-based unmet needs. Key players, such as Osel, and other companies are involved in ...Full story available on Benzinga.com